Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Lifted by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,503 shares of the biopharmaceutical company’s stock after acquiring an additional 70 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Alnylam Pharmaceuticals were worth $11,178,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after purchasing an additional 66,928 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after purchasing an additional 16,756 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after acquiring an additional 1,000 shares during the period. Eagle Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 25.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after acquiring an additional 63,385 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after purchasing an additional 8,462 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ALNY shares. Scotiabank reduced their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday. TD Cowen increased their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Piper Sandler reiterated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $299.43.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock worth $20,622,925 over the last three months. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.2 %

ALNY opened at $256.45 on Tuesday. The business has a 50 day moving average of $254.04 and a 200-day moving average of $263.44. The stock has a market capitalization of $33.08 billion, a price-to-earnings ratio of -97.88 and a beta of 0.35. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.